BDX 4.76% 10.0¢ bcal diagnostics limited

It looks like they'll go for priority TGA approval. Which makes...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,132 Posts.
    lightbulb Created with Sketch. 347
    It looks like they'll go for priority TGA approval. Which makes sense if they've got a clinic here.

    In the next phase of its work, BCAL will undertake studies designed to demonstrate the value of its test in improving diagnosis of breast cancer when it is used alongside mammography as an adjunct test, with its initial regulatory focus on seeking approval from the Australian Therapeutic Goods Administration (TGA). The TGA approval sought will be for priority review status for BCAL’s IVD test to be used as an adjunct to traditional mammogram screening. BCAL’s present and future clinical studies are also designed to support future regulatory approval pathways.
 
watchlist Created with Sketch. Add BDX (ASX) to my watchlist
(20min delay)
Last
10.0¢
Change
-0.005(4.76%)
Mkt cap ! $35.86M
Open High Low Value Volume
10.5¢ 10.5¢ 10.0¢ $53.22K 528.4K

Buyers (Bids)

No. Vol. Price($)
6 1239936 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 230435 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
BDX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.